1999: Treatment of early seropositive rheumatoid arthritis with minocycline
- From: "CaliforniaLyme" <CaliforniaLyme@xxxxxx>
- Date: 15 Feb 2006 06:32:48 -0800
1: Arthritis Rheum. 1999 Aug;42(8):1691-5. Related Articles, Links
Treatment of early seropositive rheumatoid arthritis with minocycline:
four-year followup of a double-blind, placebo-controlled trial.
O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, Eckhoff
PJ, Klassen LW, Churchill M, Doud D, Weaver A, Moore GF.
Department of Internal Medicine, University of Nebraska Medical Center,
Omaha 68198-3025, USA.
OBJECTIVE: Rheumatoid arthritis (RA) causes substantial morbidity and
mortality, and current treatments are suboptimal. Recent studies have
demonstrated the short-term efficacy of minocycline in the treatment of
patients with early RA. This study was undertaken to compare patients
treated with conventional therapy in the early phase of their RA and
those treated with minocycline, after 4 years of followup. METHODS:
Forty-six patients with seropositive RA of <1 year's duration had been
enrolled in a double-blind study of minocycline (100 mg twice daily)
versus placebo. After the blinded portion of the study (3-6 months,
depending upon response), all patients were treated with conventional
therapy. This report compares those patients randomized to receive
placebo for 3 months and then conventional therapy for the duration of
4 years versus those originally randomized to receive minocycline.
RESULTS: Twenty of the 23 original minocycline-treated patients and 18
of the 23 original placebo-treated patients were available for followup
(mean 4 years). At followup, RA was in remission (American College of
Rheumatology criteria) without disease-modifying antirheumatic drug
(DMARD) or steroid therapy in 8 of the patients originally treated with
minocycline compared with 1 patient in the placebo group (P = 0.02).
Ten patients in the minocycline group versus 16 in the original placebo
group currently require DMARD therapy (P = 0.02). CONCLUSION: Among
patients with seropositive RA, remissions are more frequent and the
need for DMARD therapy is less in those treated early in the disease
course with minocycline compared with those treated with conventional
therapy delayed by an average of only 3 months. Minocycline appears to
be an effective therapy for early RA; further investigation into its
mechanism of action is needed.
Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 10446869 [PubMed - indexed for MEDLINE]
.
- Prev by Date: 2005: Efficacy of rapamycin in patient with juvenile rheumatoid arthritis.
- Next by Date: 1996: [Diagnosis and therapy of chronic polyarthritis]
- Previous by thread: 2005: Efficacy of rapamycin in patient with juvenile rheumatoid arthritis.
- Next by thread: 1996: [Diagnosis and therapy of chronic polyarthritis]
- Index(es):
Relevant Pages
|
